NYMC Faculty Publications

Baxdrostat: An Aldosterone Synthase Inhibitor for the Treatment of Systemic Hypertension

Author Type(s)

Faculty

DOI

10.1097/CRD.0000000000000595

Journal Title

Cardiology in Review

First Page

243

Last Page

245

Document Type

Article

Publication Date

5-1-2025

Department

Medicine

Keywords

aldosterone synthase inhibitor, baxdrostat, primary aldosteronism, resistant hypertension, secondary hypertension

Disciplines

Medicine and Health Sciences

Abstract

Systemic hypertension remains one of the leading cause of morbidity and mortality in the United States and throughout the world. Baxdrostat (CIN-107), a new drug developed by Roche is a selective aldosterone synthase inhibitor that is being evaluated as one of the potential treatments for hypertension, especially in patients with drug treatment-resistant hypertension. An increased level of aldosterone is associated with inflammation, systemic hypertension, and organ fibrosis, contributing to adverse cardiovascular events. A phase 2 trial, BrigHTN, showed promising results in demonstrating the efficacy of baxdrostat, where The HALO (efficacy and safety of baxdrostat in patients with uncontrolled hypertension) trial did not demonstrate any blood pressure-lowering benefit of baxdrostat when compared with the placebo. Several additional studies are now underway to evaluate the effectiveness of baxdrostat as an anti-hypertensive agent.

Link to Full Text

Share

COinS